Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
RESEARCH TOOLSreports
Holding ARCT?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.57Last Year’s EPS
-$0.32Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -13.82%
|Next Earnings Date:Mar 03, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted the successful commercial launch of KOSTAIVE in Japan and positive clinical trial results, indicating significant progress in Arcturus' pipeline. However, financial challenges such as a decrease in revenue and a reported net loss, along with delays in data for the OTC program, were noted. Overall, the sentiment is balanced with notable achievements and ongoing challenges.Company Guidance
In the third quarter of 2024 earnings call, Arcturus Therapeutics provided several key metrics and guidance details. The company reported Q3 revenues of $41.7 million, a decrease from the previous year's $45.1 million, primarily due to a reduction in CSL revenue. However, the company received a $25 million commercial milestone following the launch of its COVID-19 vaccine, KOSTAIVE, in Japan. Arcturus reported a net loss of $6.9 million or $0.26 per diluted share for Q3 2024, compared to a net loss of $16.2 million or $0.61 per diluted share in Q3 2023. Operating expenses for the quarter were $52.4 million, down from $64.5 million in the previous year. The company anticipates that its cash runway, which stood at $294.1 million as of September 30, 2024, will extend into the first quarter of 2027. Looking ahead, Arcturus plans to file a BLA for KOSTAIVE in the U.S. in the first half of 2025, supported by positive Phase III results. Additionally, interim Phase II data for its therapeutic programs, ARCT-032 and ARCT-810, is expected in the first half of 2025.Commercial Launch of KOSTAIVE in Japan
Arcturus launched KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine, in Japan, marking the first commercial product in the company's history. They received a $25 million commercial milestone from this launch.
Positive Phase III Results for ARCT-2303
ARCT-2303, a monovalent XBB variant of KOSTAIVE, met all primary and key secondary objectives in Phase III trials, demonstrating superior immune response against Omicron variants.
FDA Clearance for ARCT-032 IND in Cystic Fibrosis
Arcturus received FDA clearance for an IND application for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, enabling the initiation of a Phase II study.
Strong Financial Position
Arcturus reported cash, cash equivalents, and restricted cash of $294.1 million as of September 30, 2024, with a projected cash runway extending into Q1 2027.
---
ARCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $18.74 | $19.62 | +4.70% |
| Aug 05, 2024 | $19.79 | $19.83 | +0.20% |
| May 08, 2024 | $27.21 | $26.79 | -1.54% |
| Mar 07, 2024 | $37.19 | $36.86 | -0.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arcturus Therapeutics (ARCT) report earnings?
Arcturus Therapeutics (ARCT) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Arcturus Therapeutics (ARCT) earnings time?
Arcturus Therapeutics (ARCT) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARCT EPS forecast?
ARCT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.57.
---
